Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Febuxostat in the management of hyperuricemia and chronic gout: a review

Authors Miao Hu, Brian Tomlinson

Published 5 December 2008 Volume 2008:4(6) Pages 1209—1220

DOI https://doi.org/10.2147/TCRM.S3310

Review by Single-blind

Peer reviewer comments 3

Miao Hu, Brian Tomlinson

Division of Clinical Pharmacology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China

Abstract: Febuxostat is a novel, potent, non-purine selective xanthine oxidase inhibitor, which in clinical trials demonstrated superior ability to lower and maintain serum urate levels below 6 mg/dL compared with conventionally used doses of allopurinol. Febuxostat was well tolerated in long term treatment in patients with hyperuricemia including those experiencing hypersensitity/intolerance to allopurinol. Dose adjustment appears unnecessary in patients with mild to moderate renal or liver insufficiency or advanced age. The most common adverse reactions reported were abnormal liver function tests, headache, and gastrointestinal symptoms, which were usually mild and transient. However, whether hepatotoxicity becomes a limitation in the use of febuxostat needs to be determined in further studies. An increased frequency of gout flares occurs for a prolonged period after treatment initiation, as with any aggressive lowering of serum urate, and prolonged prophylaxis with colchicine or NSAIDs is usually required. Febuxostat has been granted marketing authorization by the European Commission in early 2008 for the treatment of chronic hyperuricemia and gout. Febuxostat is the first major treatment alternative for gout in more than 40 years and is a promising alternative to allopurinol, although continued long-term surveillance on safety and efficacy is required.

Keywords: febuxostat, TEI-6720, TMX-67, gout, hyperuricemia, xanthine oxidase inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Current perspectives on rosuvastatin

Hu M, Tomlinson B

Integrated Blood Pressure Control 2013, 6:15-25

Published Date: 18 April 2013

Readers of this article also read:

Sustained-release nanoART formulation for the treatment of neuroAIDS

Jayant RD, Atluri VSR, Agudelo M, Sagar V, Kaushik A, Nair M

International Journal of Nanomedicine 2015, 10:1077-1093

Published Date: 4 February 2015

The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice

Fakharzadeh S, Sahraian MA, Hafizi M, Kalanaky S, Masoumi Z, Mahdavi M, Kamalian N, Minagar A, Nazaran MH

International Journal of Nanomedicine 2014, 9:3841-3853

Published Date: 11 August 2014

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes

Dardano A, Bianchi C, Del Prato S, Miccoli R

Vascular Health and Risk Management 2014, 10:465-475

Published Date: 5 August 2014

Correlation between vascular endothelial growth factor and nonperfused areas in macular edema secondary to branch retinal vein occlusion

Fujikawa M, Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M

Clinical Ophthalmology 2013, 7:1497-1501

Published Date: 19 July 2013

In vivo MRI tracking of iron oxide nanoparticle-labeled human mesenchymal stem cells in limb ischemia

Li XX, Li KA, Qin JB, Ye KC, Yang XR, Li WM, Xie QS, Jiang ME, Zhang GX, Lu XW.

International Journal of Nanomedicine 2013, 8:1063-1073

Published Date: 12 March 2013

The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice

Lee S, Kim MS, Lee D, Kwon TK, Khang D, Yun HS, Kim SH

International Journal of Nanomedicine 2013, 8:147-158

Published Date: 7 January 2013

Visual acuity and visual skills in Malaysian children with learning disabilities

Muzaliha MN, Nurhamiza B, Hussein A, Norabibas AR, Mohd-Hisham-Basrun J, Sarimah A, Leo SW, Shatriah I

Clinical Ophthalmology 2012, 6:1527-1533

Published Date: 19 September 2012

SERS-based nanobiosensing for ultrasensitive detection of the p53 tumor suppressor

Domenici F, Bizzarri AR, Cannistraro S

International Journal of Nanomedicine 2011, 6:2033-2042

Published Date: 19 September 2011